Ds Healthcare Group Comments on Recent Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Rodman & Renshaw Reinstates DS Healthcare (DSKX) at Buy
March 31, 2016 7:47 AM EDTRodman & Renshaw reinstated coverage on DS Healthcare (NASDAQ: DSKX) with a Buy rating and a price target of $1.50. Analyst Raghuram Selvaraju said clarity on accounting restatements indicates limited damage.
"In the wake of additional information disclosed by DS Healthcare regarding the scope and nature... More
